Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Net Income towards Common Stockholders of -$7.6 million for Q2 2026, up 45.89% year-over-year from -$5.2 million in Q2 2025, and up 27.23% quarter-over-quarter from -$10.5 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$7.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 45.89% year-over-year to -$7.6 million; the TTM figure through Jun 2026 stood at -$27.1 million (up 73.82% YoY), while the FY2025 annual figure was -$38.8 million, up 52.79% from the prior year.
- Net Income towards Common Stockholders advanced to -$7.6 million in Q2 2026 per AMRN's latest filing, from -$10.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.5 million in Q2 2024 and bottomed at -$70.0 million in Q2 2022.
- Historically, Net Income towards Common Stockholders has averaged -$16.9 million across 5 years, with a median of -$12.3 million in 2025.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 1841.14% — and 2024, when it surged 108.67%.
- Amarin Corp Plc\Uk's Net Income towards Common Stockholders stood at $856000.0 in 2022, then tumbled by 775.35% to -$5.8 million in 2023, then sank by 741.0% to -$48.6 million in 2024, then jumped by 97.48% to -$1.2 million in 2025, then tumbled by 525.0% to -$7.6 million in 2026.
- Business Quant data shows AMRN's Net Income towards Common Stockholders at -$7.6 million in Q2 2026, -$10.5 million in Q1 2026, and -$1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 583.63 Mn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | -7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.65 Mn |
| Mar 31, 2026 | -10.51 Mn |
| Dec 31, 2025 | -1.22 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | -14.14 Mn |
| Mar 31, 2025 | -15.70 Mn |
| Dec 31, 2024 | -48.62 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | -9.95 Mn |
| Dec 31, 2023 | -5.78 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -17.56 Mn |
| Mar 31, 2023 | -16.46 Mn |
| Dec 31, 2022 | 856,000.00 |
| Sep 30, 2022 | -5.14 Mn |
| Jun 30, 2022 | -69.96 Mn |
| Mar 31, 2022 | -31.56 Mn |
| Dec 31, 2021 | 14.70 Mn |
| Sep 30, 2021 | -13.15 Mn |